| Venetoclax and obinutuzumab in patients with CLL and coexisting conditions K Fischer, O Al-Sawaf, J Bahlo, AM Fink, M Tandon, M Dixon, S Robrecht, ... New England Journal of Medicine 380 (23), 2225-2236, 2019 | 972 | 2019 |
| Chronic lymphocytic leukemia: 2022 update on diagnostic and therapeutic procedures M Hallek, O Al‐Sawaf American journal of hematology 96 (12), 1679-1705, 2021 | 358 | 2021 |
| Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open … O Al-Sawaf, C Zhang, M Tandon, A Sinha, AM Fink, S Robrecht, ... The Lancet Oncology 21 (9), 1188-1200, 2020 | 357 | 2020 |
| Sarilumab in patients admitted to hospital with severe or critical COVID-19: a randomised, double-blind, placebo-controlled, phase 3 trial FX Lescure, H Honda, RA Fowler, JS Lazar, G Shi, P Wung, N Patel, ... The Lancet Respiratory Medicine 9 (5), 522-532, 2021 | 280 | 2021 |
| Venetoclax and obinutuzumab in chronic lymphocytic leukemia K Fischer, O Al-Sawaf, AM Fink, M Dixon, J Bahlo, S Warburton, TJ Kipps, ... Blood, The Journal of the American Society of Hematology 129 (19), 2702-2705, 2017 | 139 | 2017 |
| Nrf2 in health and disease: current and future clinical implications O Al-Sawaf, T Clarner, A Fragoulis, YW Kan, T Pufe, K Streetz, CJ Wruck Clinical science 129 (12), 989-999, 2015 | 136 | 2015 |
| Minimal residual disease dynamics after venetoclax-obinutuzumab treatment: extended off-treatment follow-up from the randomized CLL14 study O Al-Sawaf, C Zhang, T Lu, MZ Liao, A Panchal, S Robrecht, T Ching, ... Journal of Clinical Oncology 39 (36), 4049-4060, 2021 | 135 | 2021 |
| Prognostic and predictive impact of genetic markers in patients with CLL treated with obinutuzumab and venetoclax E Tausch, C Schneider, S Robrecht, C Zhang, A Dolnik, J Bloehdorn, ... Blood, The Journal of the American Society of Hematology 135 (26), 2402-2412, 2020 | 135 | 2020 |
| Bendamustine followed by obinutuzumab and venetoclax in chronic lymphocytic leukaemia (CLL2-BAG): primary endpoint analysis of a multicentre, open-label, phase 2 trial P Cramer, J von Tresckow, J Bahlo, S Robrecht, P Langerbeins, ... The Lancet Oncology 19 (9), 1215-1228, 2018 | 122 | 2018 |
| Richter transformation in chronic lymphocytic leukemia (CLL)—a pooled analysis of German CLL Study Group (GCLLSG) front line treatment trials O Al-Sawaf, S Robrecht, J Bahlo, AM Fink, P Cramer, J v Tresckow, ... Leukemia 35 (1), 169-176, 2021 | 99 | 2021 |
| Early treatment with FCR versus watch and wait in patients with stage Binet A high-risk chronic lymphocytic leukemia (CLL): a randomized phase 3 trial CD Herling, F Cymbalista, C Groß-Ophoff-Müller, J Bahlo, S Robrecht, ... Leukemia 34 (8), 2038-2050, 2020 | 89 | 2020 |
| The CLL12 trial: ibrutinib vs placebo in treatment-naïve, early-stage chronic lymphocytic leukemia P Langerbeins, C Zhang, S Robrecht, P Cramer, M Fürstenau, O Al-Sawaf, ... Blood, The Journal of the American Society of Hematology 139 (2), 177-187, 2022 | 86 | 2022 |
| Transcriptomic profiles and 5-year results from the randomized CLL14 study of venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab in chronic lymphocytic leukemia O Al-Sawaf, C Zhang, HY Jin, S Robrecht, Y Choi, S Balasubramanian, ... Nature communications 14 (1), 2147, 2023 | 76 | 2023 |
| Nrf2 augments skeletal muscle regeneration after ischaemia–reperfusion injury O Al‐Sawaf, A Fragoulis, C Rosen, N Keimes, EA Liehn, F Hölzle, ... The Journal of pathology 234 (4), 538-547, 2014 | 72 | 2014 |
| Lenalidomide maintenance after first-line therapy for high-risk chronic lymphocytic leukaemia (CLLM1): final results from a randomised, double-blind, phase 3 study AM Fink, J Bahlo, S Robrecht, O Al-Sawaf, A Aldaoud, H Hebart, ... The Lancet Haematology 4 (10), e475-e486, 2017 | 71 | 2017 |
| Using DNA sequencing data to quantify T cell fraction and therapy response R Bentham, K Litchfield, TBK Watkins, EL Lim, R Rosenthal, ... Nature 597 (7877), 555-560, 2021 | 62 | 2021 |
| Body composition and lung cancer-associated cachexia in TRACERx O Al-Sawaf, J Weiss, M Skrzypski, JM Lam, T Karasaki, F Zambrana, ... Nature medicine 29 (4), 846-858, 2023 | 51 | 2023 |
| VENETOCLAX‐OBINUTUZUMAB FOR PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA: 6‐YEAR RESULTS OF THE RANDOMIZED CLL14 STUDY. O Al‐Sawaf, S Robrecht, C Zhang, S Olivieri, YM Chang, AM Fink, ... Hematological Oncology 41, 2023 | 50* | 2023 |
| High efficacy of venetoclax plus obinutuzumab in patients with complex karyotype and chronic lymphocytic leukemia O Al-Sawaf, E Lilienweiss, J Bahlo, S Robrecht, AM Fink, M Patz, ... Blood, The Journal of the American Society of Hematology 135 (11), 866-870, 2020 | 50 | 2020 |
| CLL2-BIG: sequential treatment with bendamustine, ibrutinib and obinutuzumab (GA101) in chronic lymphocytic leukemia J von Tresckow, P Cramer, J Bahlo, S Robrecht, P Langerbeins, AM Fink, ... Leukemia 33 (5), 1161-1172, 2019 | 47 | 2019 |
